Small Molecules

20 Sep 2018 Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies
19 Sep 2018 Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
19 Sep 2018 Camurus Announces Positive Topline Phase 3 Results for CAM2038 in Opioid Experienced Patients With Chronic Low-back Pain
19 Sep 2018 CBT Pharmaceuticals Initiates the APOLLO Oncology Clinical Trials Program
19 Sep 2018 Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
19 Sep 2018 Sosei Provides Update on HTL0018318
17 Sep 2018 Eidos Therapeutics Presents Data from its Phase 1 Clinical Trial of AG10 at the 22nd Annual Scientific Meeting of the Heart Failure Society of America
17 Sep 2018 Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial and Presents Additional Data from PN Phase 2 Trial at EADV
16 Sep 2018 Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress
13 Sep 2018 First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain
13 Sep 2018 Verseon Commences Phase I Trial for Precision Oral Anticoagulant VE-1902
13 Sep 2018 M3 Biotechnology begins testing of its novel therapy NDX-1017 in individuals with Alzheimer’s disease or mild cognitive impairment
13 Sep 2018 Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with Classic Congenital Adrenal Hyperplasia
13 Sep 2018 Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment
13 Sep 2018 Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
13 Sep 2018 FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals
13 Sep 2018 Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404
13 Sep 2018 Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient
13 Sep 2018 Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
12 Sep 2018 FDA Grants Breakthrough Therapy Designation for Concentric Analgesics’ CA-008 in Post-Surgical Pain
12 Sep 2018 Merck’s ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
12 Sep 2018 KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug
12 Sep 2018 ORYZON receives approval to start ALICE: a Phase IIa clinical trial in AML with Iadademstat (ORY-1001)
12 Sep 2018 Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis
12 Sep 2018 Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up